Loading company…
Tokyo biopharmaceutical company developing Neobiologics using its LassoGraft Technology to graft cyclic peptides onto proteins.
Founded in 2017 and headquartered in Tokyo, Japan, MiraBiologics Inc. develops Neobiologics, multifunctional biopharmaceuticals made with its proprietary LassoGraft Technology, which grafts target-specific cyclic peptides onto proteins. It works largely through partnerships with pharmaceutical companies, using milestone and co-development arrangements. The company raised JPY 550 mn in Series A funding on January 15, 2020, from SBI Investment, SMBC Venture Capital and Shinsei Capital Partners, at a current valuation of JPY 6,070.588 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in